StockData

Corcept Therapeutics vs Xeris Biopharma

CORT and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CORT and XERS compare

Corcept Therapeutics is the larger company, worth 2.5 times as much as Xeris Biopharma ($7.6B against $3.1B).

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 16.0% for Corcept Therapeutics).

Corcept Therapeutics keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with −5.1% at Xeris Biopharma.

Corcept Therapeutics scores higher on the StockData Score (11 against 10 for Xeris Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCORTXERS
Size and price
Market cap$7.6B$3.1B
Share price$70.07$16.80
Change, 1 year−7.2%134%
Change, 5 years226%674%
Beta (5Y)1.360.27
Employees730435
StockData Score
Total score11 (better)10
Valuation score00
Growth score34 (better)
Performance score23 (better)
Health score6 (better)3
Dividend score00
Valuation
P/E167×–
P/S9.1× (better)9.1×
P/B10.7×–
EV/EBITDA899×84.2× (better)
P/FCF70.8×–
FCF yield1.4%–
Fair value$11.01–
Margin of safety−537%–
Growth
Revenue growth (TTM)16.0%36.3% (better)
Revenue growth, 5Y average16.6%70.2% (better)
Net income growth (TTM)−58.7%–
EPS growth (TTM)−62.5%–
EPS growth, 5Y average−0.72%–
Profitability
Gross margin98.3% (better)86.6%
Operating margin0.77%10.9% (better)
Net margin6.6% (better)−5.1%
FCF margin12.9%–
Return on equity8.2%–
Return on invested capital1.9%22.1% (better)
Financial health
Debt / equity0.00–
Net debt / EBITDA–3.45
Interest coverage–1.3×
Current ratio2.86 (better)1.45
Altman Z-score27.22 (better)3.33
Piotroski F-score48 (better)
Dividends and buybacks
Buyback yield0.56%–
Shareholder yield0.56% (better)0.00%
Ownership
Held by institutions76.2%59.4%
Held by insiders14.4%5.2%
Insider net buying, 12 months−$94.0M−$5.8M (better)
Short interest, % of float9.9%5.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.